My watch list  


rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA. It is a live vaccine, consisting of BCG genetically modified to produce abundant amounts of a 30kDa antigen that has been shown to produce a strong immune response in animals and humans. The vaccine entered clinical trials in 2004, but has since been withdrawn because of poor in vivo and in vitro potency.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RBCG30". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE